research Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
This study found that sorafenib was active against desmoid tumors, with 25% of patients achieving a partial response and 70% maintaining stable disease.
Jamshedpur, Jharkhand, India
Secunderabad, Telangana, India
Durg, Chhattisgarh, India
Bengaluru, Karnataka, India
Bodhegaon, Maharashtra, India
Mumbai, Maharashtra, India

